Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma

Saved in:
Bibliographic Details
Published inCancer cell Vol. 39; no. 8; pp. 1028 - 1030
Main Authors Van Oekelen, Oliver, Gleason, Charles R., Agte, Sarita, Srivastava, Komal, Beach, Katherine F., Aleman, Adolfo, Kappes, Katerina, Banu, Radhika, Bermúdez-González, Maria C., Chernet, Rachel L., Ferreri, Emily D., Floda, Daniel L., Firpo-Betancourt, Adolfo, Kleiner, Giulio, Russo, Kayla T., Salimbangon, Ashley-Beathrese T., Saksena, Miti S., Shin, Amber A., Matthews, Julia, Mendez, Wanni, Sominsky, Levy, Mulder, Lubbertus C.F., Mendu, Rao, Mouhieddine, Tarek H., Wang, Bo, Chari, Ajai, Cordon-Cardo, Carlos, Krammer, Florian, Jagannath, Sundar, Simon, Viviana, Wajnberg, Ania, Parekh, Samir
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 09.08.2021
Subjects
Antibody Formation
COVID-19
hematology
Humans
Letter
multiple myeloma
Multiple Myeloma - drug therapy
Multiple Myeloma - genetics
oncology
RNA
SARS-CoV-2
Vaccination
vaccine
COVID-19
vaccine
multiple myeloma
SARS-CoV-2
hematology
oncology
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
ObjectType-Commentary-3
content type line 23
ISSN:1535-6108
1878-3686
1878-3686
DOI:10.1016/j.ccell.2021.06.014